| Schedule of Segment Financial Information |
The following table summarizes the reportable segment's financial information (in thousands): | | | | | | | | | | Three Months Ended March 31, | | 2025 | 2024 | | | | Revenue | $ | 93,881 | | $ | 70,502 | | Less: | | | Cost of revenue from sale of therapies | (831) | | (246) | | External research and development (R&D) expenses: | | | | PRAME programs | (17,305) | | (26,700) | | | Tebentafusp programs | (7,990) | | (5,894) | | | Infectious disease programs | (1,405) | | (2,246) | | All other external clinical and preclinical costs | (11,231) | | (6,499) | | | Total external R&D expenses | (37,931) | | (41,339) | | | R&D salaries and other employee-related costs | (11,043) | | (9,754) | | Selling, general and administrative (SG&A) salaries and other employee-related costs | (12,218) | | (14,840) | | Other SG&A expenses | (20,672) | | (17,463) | | Other segment expense, net (a) | (6,163) | | (11,296) | | Segment and consolidated net income (loss) | $ | 5,023 | | $ | (24,436) | |
|